利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.014 秒)

    Pharmaceutical compositions comprising an hiv envelope protein and cd4
    1.
    发明申请
    Pharmaceutical compositions comprising an hiv envelope protein and cd4 审中-公开
    包含hiv包膜蛋白和cd4的药物组合物

    公开(公告)号：US20060142219A1

    公开(公告)日：2006-06-29

    申请号：US10524549

    申请日：2003-08-12

    申请人： Paolo Lusso ,  Samuele Burastero

    发明人： Paolo Lusso ,  Samuele Burastero

    IPC分类号： A61K48/00 ,  C12N15/867

    CPC分类号： C12N15/62 ,  A61K38/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/70514 ,  C07K16/1063 ,  C07K16/2812 ,  C07K2317/32 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/32 ,  C07K2319/40 ,  C12N5/0634 ,  C12N2710/24143 ,  C12N2740/16122 ,  C12N2740/16134

    摘要： Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein. Also disclosed are pharmaceutical compositions for treating/preventing HIV comprising an antibody immunospecific for a fixed cell expressing an HIV envelope protein complex with a CD4 receptor protein. The binding of the CD4 to the HIV envelope protein, i.e. gp120, exposes hidden epitopes that may be used as targets in immunotherapy; the presentation of the gp120 and CD4 in the present forms is said to overcome problems with prior art soluble gp120-CD4 complexes.

    摘要翻译： 用于治疗/预防HIV的药物组合物，包括（i）编码HIV包膜蛋白的多核苷酸和（ii）编码CD4受体蛋白的多核苷酸; （i）编码HIV包膜蛋白的多核苷酸和（ii）CD4受体蛋白; 表达与CD4受体蛋白质复合的HIV包膜蛋白的固定细胞。 还公开了用于治疗/预防HIV的药物组合物，其包含针对表达具有CD4受体蛋白质的HIV包膜蛋白复合物的固定细胞的免疫特异性抗体。 CD4与HIV包膜蛋白（即gp120）的结合暴露了可用作免疫治疗靶标的隐藏表位; 据说现有形式的gp120和CD4的表达克服了现有技术可溶性gp120-CD4复合物的问题。

    Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication
    2.
    发明申请
    Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication 有权
    使用疱疹病毒，疱疹病毒蛋白和编码蛋白质的核酸来抑制ccr5-嗜性Hiv-1感染和复制

    公开(公告)号：US20050123510A1

    公开(公告)日：2005-06-09

    申请号：US10473560

    申请日：2002-03-28

    申请人： Leonid Margolis ,  Jean-Charles Grivel ,  Paolo Lusso

    发明人： Leonid Margolis ,  Jean-Charles Grivel ,  Paolo Lusso

    IPC分类号： A61K35/76 ,  A61K35/763 ,  A61K38/16 ,  A61K48/00

    CPC分类号： A61K38/162 ,  A61K35/763 ,  A61K48/00 ,  C12N2710/16532

    摘要： It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.

    摘要翻译： 已经发现，疱疹病毒可以引发HIV抑制趋化因子的产生增加，并且这些趋化因子阻断CCR5受体，其被用作HIV-1的CCR5-热带形式的CD4的共受体，其主要是 在早期HIV-1感染。 使用活的，减毒的或杀死的疱疹病毒，或引发HIV抑制趋化因子产生增加的疱疹病毒蛋白质，或编码这些蛋白质的核酸也可用于预防HIV-1感染的建立或抑制HIV- 1复制。 本发明提供了与这些发现相关的用途，方法和组合。

    Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication
    7.
    发明授权
    Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication 有权
    使用疱疹病毒，疱疹病毒蛋白和编码蛋白质的核酸来抑制CCR5-嗜性HIV-1感染和复制

    公开(公告)号：US07968298B2

    公开(公告)日：2011-06-28

    申请号：US10473560

    申请日：2002-03-28

    申请人： Leonid B. Margolis ,  Jean-Charles Grivel ,  Paolo Lusso

    发明人： Leonid B. Margolis ,  Jean-Charles Grivel ,  Paolo Lusso

    IPC分类号： C12Q1/70 ,  G01N33/53

    CPC分类号： A61K38/162 ,  A61K35/763 ,  A61K48/00 ,  C12N2710/16532

    摘要： It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.

    摘要翻译： 已经发现，疱疹病毒可以引发HIV抑制趋化因子的产生增加，并且这些趋化因子阻断CCR5受体，其被用作HIV-1的CCR5-热带形式的CD4的共受体，其主要是 在早期HIV-1感染。 使用活的，减毒的或杀死的疱疹病毒，或引发HIV抑制趋化因子产生增加的疱疹病毒蛋白质，或编码这些蛋白质的核酸也可用于预防HIV-1感染的建立或抑制HIV- 1复制。 本发明提供了与这些发现相关的用途，方法和组合。